Sign up for a free trial now
  • Login
  • Subscribe
  • Take a FREE Trial
  • About Us
  • Contact us
  • RSS

20 May 2013


The Pharma Letter
  • Home
  • 7 Day Premium Trial
  • Pharmaceuticals
  • Biotechnology
  • Generics
  • Events
  • Companies
  • Drugs
  • Subscribe

Takeda Pharmaceuticals America Articles

Add-on benefits of Actos shown in study

20 June 2005

Japan stock market week to June 10

20 June 2005

B-M Squibb/Merck & Co's Pargluva: good PhI/II

20 June 2005

Japan stock market week to May 30

6 June 2005

Weak performance at TAP takes its toll on Takeda's FY to March 2005

30 May 2005

Takeda breaks ground on new US site

16 May 2005

Sankyo and Daiichi prepare to merge?

28 February 2005

CORRECTION: Takeda's ramelteon is not FDA approved

10 January 2005

Takeda's Actoplus Met filed in USA

8 November 2004

Takeda No 1 in "corporate excellence" in Japan

4 October 2004

New president of TAP Pharma named

6 September 2004

Takeda sets up North America diabetes research grant

23 June 2003

Takeda anticipates 10th successive record profit

20 May 2002

TAP gets fast-track review of Prevacid for children

22 April 2002

Tokyo pharma stocks - week to February 18

25 February 2002

Aventis gets OK for Actonel in Japan

28 January 2002

Takeda/Lilly underwrite US Rx cost/benefit report

19 October 2001

Japan pharma stock market - week to October 15

17 October 2001

Takeda North America appointments

20 September 2001

Stock Commentary Tokyo

11 May 2000

Takeda Entering New Product Cycle

21 September 1998

Takeda Pharma Sets Up Swiss Subsidiary

11 September 1998

New Takeda Subsidiary

23 January 1995

TAKEDA NEW SUSTAIN RELEASE DEVELOPMENT

3 August 1992

Showing 201-224 of 224 articles

Go to beginningPrevious
  • 1
  • 2
  • 3
NextGo to end
  • Hot Topics
  • Most Read
  • Elan makes "transformational" acquisitions and a divestment
  • Drug prices to plunge as Indian government announces plans to regulate rates of 652 medicines
  • SciClone gains China rights to Zensun's Neucardin
  • Bristol-Myers' data on Yervoy and nivolumab causes a stir
  • Boehringer Ingelheim transitions to propellant-free Combivent Respimat; names new BMD member
  • Elan makes "transformational" acquisitions and a divestment
  • Drug prices to plunge as Indian government announces plans to regulate rates of 652 medicines
  • SciClone gains China rights to Zensun's Neucardin
  • Bristol-Myers' data on Yervoy and nivolumab causes a stir
  • Boehringer Ingelheim transitions to propellant-free Combivent Respimat; names new BMD member

30 Day Premium Trial


Events

Twitter Right banner

RSS



© 2013 thepharmaletter.com

  • Home
  • RSS
  • About Us
  • Subscribe
  • Terms and Conditions
  • Article Archive
Site powered by WORKSsitebuilder CMS